Interventional, Open-label, Multiple-dose Study to Investigate the Effects of Multiple Doses of Lu AF35700 on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Dextromethorphan (CYP2D6), Caffeine (CYP1A2), Omeprazole (CYP2C19), and Midazolam (CYP3A4/5) in Healthy Young Adults

Trial Profile

Interventional, Open-label, Multiple-dose Study to Investigate the Effects of Multiple Doses of Lu AF35700 on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Dextromethorphan (CYP2D6), Caffeine (CYP1A2), Omeprazole (CYP2C19), and Midazolam (CYP3A4/5) in Healthy Young Adults

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs LU AF-35700 (Primary) ; Midazolam
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 08 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
    • 08 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
    • 27 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top